ES2055587T3 - El uso de agonistas selectivos de gaba-b como agentes antitusivos. - Google Patents

El uso de agonistas selectivos de gaba-b como agentes antitusivos.

Info

Publication number
ES2055587T3
ES2055587T3 ES91902534T ES91902534T ES2055587T3 ES 2055587 T3 ES2055587 T3 ES 2055587T3 ES 91902534 T ES91902534 T ES 91902534T ES 91902534 T ES91902534 T ES 91902534T ES 2055587 T3 ES2055587 T3 ES 2055587T3
Authority
ES
Spain
Prior art keywords
agonists
selective gaba
tussive agents
gaba
selective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91902534T
Other languages
English (en)
Inventor
William Kreutner
Donald Bolser
Richard Chapman
Sultan Aziz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2055587T3 publication Critical patent/ES2055587T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

EL USO DE AGONISTAS SELECTIVOS DE GABA-B COMO AGENTES ANTITUSIVOS SE INVENTA EL USO DE AGONISTAS SELECTIVOS DE GABA-B COMO BACLOFEN PARA EL TRATAMIENTO DE LA TOS.
ES91902534T 1989-12-20 1990-12-18 El uso de agonistas selectivos de gaba-b como agentes antitusivos. Expired - Lifetime ES2055587T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/454,786 US5006560A (en) 1989-12-20 1989-12-20 Use of GABA-B selective agonists as anti-tussive agents

Publications (1)

Publication Number Publication Date
ES2055587T3 true ES2055587T3 (es) 1994-08-16

Family

ID=23806078

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91902534T Expired - Lifetime ES2055587T3 (es) 1989-12-20 1990-12-18 El uso de agonistas selectivos de gaba-b como agentes antitusivos.

Country Status (14)

Country Link
US (1) US5006560A (es)
EP (1) EP0506853B1 (es)
JP (1) JPH06102630B2 (es)
KR (1) KR950007208B1 (es)
AT (1) ATE106725T1 (es)
AU (1) AU642969B2 (es)
CA (1) CA2071981C (es)
DE (1) DE69009778T2 (es)
DK (1) DK0506853T3 (es)
ES (1) ES2055587T3 (es)
FI (1) FI922798L (es)
HU (1) HU212271B (es)
OA (1) OA09702A (es)
WO (1) WO1991008740A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229404A (en) * 1988-05-18 1993-07-20 Novo Nordisk A/S Azacyclic carboxylic acid derivatives and their preparation and use
US5214054A (en) * 1988-05-18 1993-05-25 Novo Nordisk A/S Azacyclic carboxylic acid derivatives and their preparation and use
US5231106A (en) * 1988-05-18 1993-07-27 Novo Nordisk A/S Azacyclic carboxylic acid derivatives and their preparation and use
DK588189D0 (da) * 1989-11-22 1989-11-22 Novo Nordisk As Nye heterocykliske carboxylsyrer
US5182266A (en) * 1990-01-31 1993-01-26 Abbott Laboratories Method for treating renal disease
FR2662354B1 (fr) * 1990-05-23 1994-10-07 Adir Utilisation du baclofene pour l'obtention de medicaments destines au traitement de l'angine de poitrine.
GB9117716D0 (en) * 1991-08-16 1991-10-02 Lynxvale Ltd Gaba derivatives and their therapeutic application
US6194460B1 (en) * 1995-05-31 2001-02-27 Montefiore Medical Center Composition for treating cough induced by angiotensin converting enzyme inhibitors
WO1997043902A1 (en) * 1996-05-24 1997-11-27 Smithkline Beecham Corporation Use of gaba uptake inhibitors as anti-tussive agents
HU228771B1 (en) * 1998-05-15 2013-05-28 Warner Lambert Co Stabilized pharmaceutical preparations of gamma-aminobutyric acid derivatives and process for preparing the same
US7319095B2 (en) 1999-12-09 2008-01-15 Astrazeneca Ab Use of GABAB receptor agonists
SE9904508D0 (sv) 1999-12-09 1999-12-09 Astra Ab New compounds
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
KR101140559B1 (ko) * 2003-08-20 2012-07-05 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
WO2006050471A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
WO2006050472A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
US20060160777A1 (en) * 2004-12-27 2006-07-20 Anders Lehmann New use of GABAbeta receptor agonists
WO2008033572A1 (en) * 2006-09-15 2008-03-20 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
WO2008086492A1 (en) * 2007-01-11 2008-07-17 Xenoport, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
TW200936123A (en) * 2007-11-06 2009-09-01 Xenoport Inc Use of prodrugs of GABAb agonists for treating neuropathic and musculoskeletal pain
JP5563483B2 (ja) * 2008-01-25 2014-07-30 ゼノポート，インコーポレイティド アシロキシアルキルカルバメートプロドラッグの合成に使用されるアシロキシアルキルチオカーボネートの鏡像異性的な分解
US7872046B2 (en) * 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
US20100137442A2 (en) * 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
EP2309858A4 (en) 2008-07-31 2011-09-14 Dekel Pharmaceuticals Ltd COMPOSITIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES
WO2010017498A1 (en) 2008-08-07 2010-02-11 Xenoport, Inc. Methods of synthesizing n-hydroxysuccinimidyl carbonates
US8299291B2 (en) * 2008-08-07 2012-10-30 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
CA2753057C (en) * 2009-03-03 2018-09-11 Xenoport, Inc. Sustained release oral dosage forms of an r-baclofen prodrug
WO2010120370A2 (en) * 2009-04-17 2010-10-21 Xenoport, Inc. Gamma-amino-butyric acid derivatives as gabab receptor ligands
WO2013023155A1 (en) 2011-08-11 2013-02-14 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH449645A (de) * 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren

Also Published As

Publication number Publication date
EP0506853B1 (en) 1994-06-08
HU212271B (en) 1996-04-29
FI922798A0 (fi) 1992-06-17
EP0506853A1 (en) 1992-10-07
KR920703043A (ko) 1992-12-17
ATE106725T1 (de) 1994-06-15
DE69009778D1 (de) 1994-07-14
CA2071981A1 (en) 1991-06-21
JPH06102630B2 (ja) 1994-12-14
FI922798A7 (fi) 1992-06-17
DK0506853T3 (da) 1994-08-01
FI922798L (fi) 1992-06-17
HU9202077D0 (en) 1992-09-28
US5006560A (en) 1991-04-09
JPH05504764A (ja) 1993-07-22
HUT61194A (en) 1992-12-28
DE69009778T2 (de) 1994-09-22
AU642969B2 (en) 1993-11-04
KR950007208B1 (ko) 1995-07-04
CA2071981C (en) 2002-06-25
AU7174591A (en) 1991-07-18
OA09702A (en) 1993-08-30
WO1991008740A1 (en) 1991-06-27

Similar Documents

Publication Publication Date Title
ES2055587T3 (es) El uso de agonistas selectivos de gaba-b como agentes antitusivos.
ES2154741T3 (es) Uso de agentes de union a cd23 en el tratamiento de enfermedades autoinmunes.
ES2179351T3 (es) Amidas acidas de piridil alqueno y piridil alquino como citoestaticos e inmunosupresores.
FI900153A0 (fi) Administreringsanordningar baserade pao hydrogel.
PT93351A (pt) Metodo para a utilizacao de derivados de 4-fenil-1,2,3,4-tetra-hidro-1- -naftalenamina no tratamento de psicose, inflamacao e como imunosupressores
PT804196E (pt) Utilizacao de antagonistas de serotonina (5ht3) para o tratamento de fibromialgia
ES2055406T3 (es) Composicion para el tratamiento de la inflamacion.
ES2063202T3 (es) Nuevas 5,11-dihidro-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepin-6-onas y -tionas y su uso en la prevencion o tratamiento del sida.
AR016981A2 (es) Polipeptidos sinteticos
AR241082A1 (es) Nuevos derivados de pirazol utiles como agentes herbicidas, las composiciones herbicidas que los contienen y los procedimientos para producir estos derivados de pirazol".
ES2083597T3 (es) Preparacion farmaceutica para el tratamiento del tiempo de coagulacion prolongado.
DK0457849T3 (da) Klæbemiddel til elektrotransport
ES2013631B3 (es) Metodo para el tratamiento de tejidos.
ES2035859T3 (es) Composicion abrillantadora para pisos.
DE68915503D1 (de) Zahnchirurgisches Gerät, geeignet für die Versorgung von gekoppelten Handstücken mit drei unterschiedlichen Fluida.
ES2135722T3 (es) 1,5-benzodiacepinas 5-heterociclicas moduladoras de la cck o de la gastrina.
ES2059457T3 (es) Utilizacion de bezafibrato para el tratamiento de la diabetes.
ES2052850T3 (es) Un procedimiento para preparar un compuesto de hidrazona.
ES2073391T3 (es) Metodo y composiciones terapeuticas para el tratamiento de trastornos de perdidas de sangre.
ES2087279T3 (es) El uso de giberelinas para el tratamiento de la prostatitis y la psoriasis.
ES2066096T3 (es) 4-bencil-5-fenil-2,4-dihidro-3h-1,2,4-triazol-3-onas y su uso como anticonvulsivos.
DK207086A (da) Anvendelse af dopaminagonister
ES2032914T3 (es) Procedimiento para preparar composiciones con diclorotrifluoetano.
ES2085051T3 (es) Usos de 1,1,1,3,3,3-hexafluoropropano.
ES2056876T3 (es) Compuestos piperidinilicos 1,4-disustituidos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 506853

Country of ref document: ES